Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Otto Buttula
Date of last notice	3 September 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	 Newfound Investments Pty Ltd <newfound a="" c="" fund="" super=""></newfound> Webinvest Pty Ltd <olsb a="" c="" unit=""></olsb>
Date of change	9 September 2021
No. of securities held prior to change	 Newfound Investments Pty Ltd <newfound a="" c="" fund="" super=""> 10,733,333 fully paid ordinary shares</newfound> Webinvest Pty Ltd <olsb a="" c="" unit=""> 16,666,667 fully ordinary paid shares</olsb>
Class	 a) Fully paid ordinary shares (ASX: RHY) b) Unlisted options (ASX: RHYAK) expiring 31 August 2022 c) Unlisted options (ASX: RHYAL) expiring 31 July 2024

⁺ See chapter 19 for defined terms.

Number acquired	a) 685,001 b) 342,501 c) 342,501
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$582,251
No. of securities held after change	 Newfound Investments Pty Ltd <newfound a="" c="" fund="" super=""> 11,001,667 fully paid ordinary shares (ASX:RHY)</newfound> 134,167 Unlisted options (ASX:RHYAK) expiring 31 August 2022 134,167 Unlisted options (ASX: RHYAL) expiring 31 July 2024 Webinvest Pty Ltd <olsb a="" c="" unit=""> 17,083,334 fully ordinary paid shares (ASX:RHY)</olsb> 208,334 Unlisted options (ASX:RHYAK) expiring 31 August 2022 208,334 Unlisted options (ASX:RHYAK) expiring 31 August 2022 208,334 Unlisted options (ASX: RHYAL) expiring 31 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of offer pursuant to non- renounceable rights issue lodged with ASX on 30 July 2021.

Detail of contract	n/a
Notice of interest	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	

⁺ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lou Panaccio
Date of last notice	3 September 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Tercus Pty Ltd
Date of change	9 September 2021
No. of securities held prior to change	Held by Beneficial interest held through Tercus Pty Ltd 800,000 fully paid ordinary shares
Class	 Fully paid ordinary shares (ASX: RHY) Unlisted options (ASX: RHYAK) expiring 31 August 2022 Unlisted options (ASX: RHYAL) expiring 31 July 2024
Number acquired	1) 20,000 2) 10,000 3) 10,000
Number disposed	Nil

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$17,000
No. of securities held after change	Held by Beneficial interest held through Tercus Pty Ltd
	820,000 fully paid ordinary shares (ASX:RHY) 10,000 Unlisted options (ASX:RHYAK) expiring 31 August 2022 10,000 Unlisted options (ASX: RHYAL)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of offer pursuant to non- renounceable rights issue lodged with ASX on 30 July 2021.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

⁺ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Eduardo Vom
Date of last notice	3 September 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2021
No. of securities held prior to change	 Eduardo Vom - 1,136,000 fully paid ordinary shares Natalie Patterson (spouse) - 2,416,667 fully paid ordinary shares
Class	 a) Fully ordinary paid shares (ASX: RHY) b) Unlisted options (ASX: RHYAK) expiring 31 August 2022 c) Unlisted options (ASX: RHYAL) expiring 31 July 2024
Number acquired	a) 88,817 b) 44,409 c) 44,409

⁺ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$75,494
No. of securities held after change	 Eduardo Vom Eduardo Vom 1,164,400 fully paid ordinary shares (ASX:RHY) 14,200 Unlisted options (ASX:RHYAK) expiring 31 August 2022 14,200 Unlisted options (ASX: RHYAL) expiring 31 July 2024 Natalie Patterson (spouse) - 2,477,084 fully paid ordinary shares (ASX:RHY) 30,209 Unlisted options (ASX:RHYAK) expiring 31 August 2022 30,209 Unlisted options (ASX: RHYAL) expiring 31 August 2022 30,209 Unlisted options (ASX: RHYAL)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of offer pursuant to non- renounceable rights issue lodged with ASX on 30 July 2021.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Trevor Lockett
Date of last notice	20 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2021
No. of securities held prior to change	160,000 fully paid ordinary shares held by Mrs Linda Jane Lockett & Dr Trevor John Lockett 1,500,000 unlisted options held by Mrs Linda Jane Lockett & Dr Trevor John Lockett to acquire fully paid ordinary shares having an exercise price of \$0.20 and expiring 14 September 2023.
Class	 Fully paid ordinary shares (ASX: RHY) Unlisted options (ASX: RHYAK) expiring 31 August 2022 Unlisted options (ASX: RHYAL) expiring 31 July 2024

⁺ See chapter 19 for defined terms.

Number acquired	1) 4,000
	2) 2,000
	3) 2,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,400
No. of securities held after change	164,000 fully paid ordinary shares held by Mrs Linda Jane Lockett & Dr Trevor John Lockett (ASX:RHY)
	1,500,000 unlisted options held by Mrs Linda Jane Lockett & Dr Trevor John Lockett to acquire fully paid ordinary shares having an exercise price of \$0.20 and expiring 14 September 2023.
	2,000 Unlisted options (ASX:RHYAK) expiring 31 August 2022 2,000 Unlisted options (ASX: RHYAL) expiring 31 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of offer pursuant to non- renounceable rights issue lodged with ASX on 30 July 2021.

Detail of contract	n/a
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	

⁺ See chapter 19 for defined terms.

Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.